866-997-4948(US-Canada Toll Free)

Encephalopathy - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 54 Pages

Encephalopathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy Pipeline Review, H2 2016, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Encephalopathy.

Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Encephalopathy Overview 7
Therapeutics Development 8
Pipeline Products for Encephalopathy - Overview 8
Pipeline Products for Encephalopathy - Comparative Analysis 9
Encephalopathy - Therapeutics under Development by Companies 10
Encephalopathy - Therapeutics under Investigation by Universities/Institutes 11
Encephalopathy - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Encephalopathy - Products under Development by Companies 14
Encephalopathy - Products under Investigation by Universities/Institutes 15
Encephalopathy - Companies Involved in Therapeutics Development 16
Celgene Corp 16
Chiesi Farmaceutici SpA 17
Fera Pharmaceuticals LLC 18
GW Pharmaceuticals Plc 19
JS Genetics Inc 20
ProThera Biologics Inc 21
SciFluor Life Sciences LLC 22
Turing Pharmaceuticals AG 23
Zambon Company SpA 24
Encephalopathy - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Alda-1 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
diazoxide - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
GWP-42003 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
melatonin - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
ORP-006 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
phenobarbitol sodium - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SF-0034 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Stem Cell Therapy for Hematological Malignancies, Hypoxic-ischemic Encephalopathy and Solid Tumor - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
TRP-005 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
TRP-601 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
TUR-004 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ZP-053 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Encephalopathy - Product Development Milestones 50
Featured News & Press Releases 50
Nov 16, 2015: Turing Initiates Dosing in Phase I Clinical Trial of TUR 004 for Epileptic Encephalopathies 50
Oct 23, 2015: Turing Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application and Fast Track Designation for TUR-004 50
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development for Encephalopathy, H2 2016 8
Number of Products under Development for Encephalopathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Encephalopathy - Pipeline by Celgene Corp, H2 2016 16
Encephalopathy - Pipeline by Chiesi Farmaceutici SpA, H2 2016 17
Encephalopathy - Pipeline by Fera Pharmaceuticals LLC, H2 2016 18
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H2 2016 19
Encephalopathy - Pipeline by JS Genetics Inc, H2 2016 20
Encephalopathy - Pipeline by ProThera Biologics Inc, H2 2016 21
Encephalopathy - Pipeline by SciFluor Life Sciences LLC, H2 2016 22
Encephalopathy - Pipeline by Turing Pharmaceuticals AG, H2 2016 23
Encephalopathy - Pipeline by Zambon Company SpA, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33

List of Figures
Number of Products under Development for Encephalopathy, H2 2016 8
Number of Products under Development for Encephalopathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Targets, H2 2016 26
Number of Products by Stage and Targets, H2 2016 26
Number of Products by Mechanism of Actions, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *